Stemtech Corporation has signed a non-binding Letter of Intent (LOI) for a proposed Reverse Takeover (RTO) with Eevia Health Plc, a Finnish producer of organic plant extracts and nutraceuticals listed on the Swedish Spotlight Stock Market under the symbol "EEVIA". Under the RTO, Eevia will acquire the assets of Stemtech and Seacret Direct, LLC, also known as Viago. The resulting ownership will consist of approximately 85% Stemtech and 15% Eevia shareholders. Final terms are subject to due diligence and negotiation.
Additionally, Stemtech intends to execute a merger with Viago, making it a wholly owned subsidiary, with plans for certain management changes and rebranding into a public holding company with separate subsidiaries. This merger is subject to various conditions including financial audits, stockholder approvals, and the right to terminate under certain customary conditions by June 25, 2025. Names mentioned include Eevia Health Plc, Seacret Direct, LLC / Viago, Izhak Ben Shabbat, John W. Meyer, and Eddie Head.